Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. - Wikidata - awgldk - TriplyDB

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.

http://www.wikidata.org/entity/Q33903723

about

Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis XPF-673C>T polymorphism effect on the susceptibility to esophageal cancer in Chinese population RNA-seq reveals determinants of sensitivity to chemotherapy drugs in esophageal carcinoma cells.Individual patient oesophageal cancer 3D models for tailored treatment.Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer Predicting response to neoadjuvant therapy in esophageal cancer.ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.Association of nuclear annexin A1 with prognosis of patients with esophageal squamous cell carcinoma.Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report.The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer.Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review.Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer.Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine.Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas.Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes.Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases.

P2860

Q27852996-52536ADB-2657-4FA0-B6EC-0B5EB0B0CAF5 Q31157907-37EE7881-B2C4-46FD-8944-5C6F3F73641A Q33582964-F0C2990B-74D7-4CD4-92D5-19807EC61189 Q33648440-35DBCCBB-1D09-4983-8C2D-64807FAC73C0 Q33728359-B7ABE262-DFC4-4E06-A27E-C5BB7F0A9153 Q34022135-56AFE315-6431-41CF-8FAF-1C1803D3154B Q34142322-F9F96A73-12F1-4223-AFD9-6156DD58441A Q35175390-1F4C5C3F-AD18-4692-B3F0-2E9563F88DE5 Q35272401-A3E704B8-7701-49B5-937E-54BB167EC8B9 Q35632327-F48D5515-326B-49BB-8B4A-B94E322F3E67 Q35633809-1CFDA590-6E4D-4B8F-BF67-90CC947A8C2C Q35915297-A6576058-2A81-4BC5-9384-EF9EDAE48F64 Q36931470-18EC0D1D-C9B6-47BF-A265-D54AEC8A7641 Q37439912-2FE7609A-2303-43F8-80F7-1F78B4A16112 Q37520516-904FEB20-596F-4A49-B7BB-299FAEFF42BE Q37587416-7DA0C250-5D3B-4EE4-8E22-43A561A93AC8 Q37609288-29FB7082-6355-4C24-BF0F-B4D5BD7097CE Q37818224-A11A05A5-F31B-4583-9246-C94061BE75C7 Q38397658-D6222589-9FBA-457F-AE79-C6975490A239 Q38687715-0381AD60-53B1-43BE-9A38-F3786CFDFA8B Q38894951-C1AE4281-C419-4D72-8AC2-029AA4DE1516 Q39065414-A5B4B21E-253A-4D2C-80AF-86E22E664097 Q39199269-7534A6A1-98EB-4ABC-BBC5-97AC4A3E22B4 Q40282337-EB46AAE9-1B37-4F15-B4DB-AB2544953B82 Q40309779-C9E83D2D-DBEB-41CB-B8E6-2AD1DD92611F Q41205616-7AE90285-A5F3-41F2-96EE-F28558111264 Q41961362-1E1DFA9B-85FF-48C7-BCEC-F0A84B3DEAD2 Q42332601-C80D8C15-AA34-4730-ACDB-DCA1CC1C03D5 Q44143001-75304FF4-10B9-45BD-86D2-9154832E9900 Q44793365-63DE30B1-1739-4091-9301-8C606DE4798B Q47146363-F0506996-EBDB-4B09-9FCA-14E458BEAE47 Q47154860-2AB332BC-2B9E-4F0F-AB49-8CF50A5B6049 Q47655628-269A42B3-C6FB-478B-B866-7DE3EB14201F Q50999929-674BB702-5E3B-459E-A0BA-8FA8780D2F28 Q55424081-225EA8F0-934D-45FB-A026-D25DFC6D59AC

P2860

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.

http://www.wikidata.org/entity/Q33903723

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Tumour regression and ERCC1 nu ...... with neoadjuvant chemotherapy.

@ast

Tumour regression and ERCC1 nu ...... with neoadjuvant chemotherapy.

@en

type

label

Tumour regression and ERCC1 nu ...... with neoadjuvant chemotherapy.

@ast

Tumour regression and ERCC1 nu ...... with neoadjuvant chemotherapy.

@en

prefLabel

Tumour regression and ERCC1 nu ...... with neoadjuvant chemotherapy.

@ast

Tumour regression and ERCC1 nu ...... with neoadjuvant chemotherapy.

@en

P1433

Q33903723-F9308BEA-C03F-4811-AB7D-3A559E809D00

P1476

Q33903723-0AD1F173-74C2-41AA-83AD-D89B48B882FA

P2093

Q33903723-1F50CD4B-B48B-4D6D-9085-763F2298F087

Q33903723-27E25D3F-BB01-45F8-BD35-6BBFCE086D9A

Q33903723-362B01FA-2A89-47BB-926B-E0072E458EF6

Q33903723-3A8109E8-4AA5-41B0-9C8C-AAEA4E36BC42

Q33903723-4A1390CC-71EA-42C3-936D-5EFED1C241AF

Q33903723-6E302BCB-5726-4928-B69A-E9D72A95ADC0

Q33903723-7AB42365-7146-4716-8395-02E46FCFAD83

Q33903723-8261F2A5-F922-4931-A66F-5C0D467CF131

P2860

Q33903723-0189D9F4-DE6F-41B1-8743-CC3365257FE3

Q33903723-08A443F7-404C-456C-ABA1-BFBD66633278

Q33903723-0936A4A9-0A48-4D23-A454-89C231C7CB72

Q33903723-10920587-021A-4B8F-8FE7-750F0396F194

Q33903723-29A1D4A1-D4B1-4473-8350-57E85A73F5BF

Q33903723-2A72DD16-1EDD-4C21-B371-B7F523AF2E95

Q33903723-30118189-8650-416B-8BE3-1B05A5A63F48

Q33903723-344F0AFE-84B7-4B14-956E-219DD4D954A9

Q33903723-413D28CB-E4C3-40D2-92B1-E8EA32C18E76

Q33903723-41EE1AF6-34C0-4DDB-B031-34FF0FC83843

P2888

Q33903723-428CEB76-76DC-4E4F-9445-81CEE18D19BC

P304

Q33903723-AFC29E52-9B3B-4B2F-926C-3ADAE65282AA

P31

Q33903723-647DD2E7-D03C-4692-8E76-A6F5A728E872

P356

Q33903723-5BEC341C-577B-4FA9-96E3-870DDE7EB71A

P407

Q33903723-0CD4360A-8EDA-4285-892A-842F09FE1F4B

P433

Q33903723-D2C01D3E-36EE-4E87-9716-2F5AB49AAB35

P478

Q33903723-4A1EC7A0-B1B3-4347-B248-EAD78ECDD4E8

P577

Q33903723-D4164DE1-3B9C-4AED-845A-05F68ACF5D65

P5875

Q33903723-77BF9011-CF48-47B0-B93F-907C2F199FEA

P6179

Q33903723-4B70FB1C-A8E1-4679-8192-7387D43CCF3D

P698

Q33903723-F45667A7-DA27-481A-B98D-BFE048371E97

P921

Q33903723-DC77A04B-8AD8-4E9C-AD32-0256F8CDDB02

P932

Q33903723-B2DEEC8C-D353-4CAA-B1C8-DC12BEFF002C

P356

P1433

British Journal of Cancer

P1476

Tumour regression and ERCC1 nu ...... with neoadjuvant chemotherapy.

@en

P2093

A Al-Attar

http://www.w3.org/2001/XMLSchema#string

D N Lobo

http://www.w3.org/2001/XMLSchema#string

I N Soomro

http://www.w3.org/2001/XMLSchema#string

J Patel

http://www.w3.org/2001/XMLSchema#string

K R Fareed

http://www.w3.org/2001/XMLSchema#string

P V Kaye

http://www.w3.org/2001/XMLSchema#string

S L Parsons

http://www.w3.org/2001/XMLSchema#string

S Madhusudan

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

The Fanconi anaemia/BRCA pathway

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers.

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

P2888

P304

1600-1607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605686

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44590798

http://www.w3.org/2001/XMLSchema#string

P6179

1003929252

http://www.w3.org/2001/XMLSchema#string

P698

20461087

http://www.w3.org/2001/XMLSchema#string

P921

P932

2883154

http://www.w3.org/2001/XMLSchema#string